Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Jacqueline Weingarten-Arams

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weingarten_Jacqueline_MD_420x504.jpg

First Name

Jacqueline

Last Name

Weingarten-Arams

NPI

1558447409

Faculty ID

4831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

3961

Biography

<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams&rsquo; pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly&rsquo;s &ldquo;Top Doctors: New York Metro Area&rdquo; for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>

Is Open Scheduling

Off

Mark I. Travin

https://assets.montefioreeinstein.org/profiles/images/physphoto/Travin_Mark_MD_420x504.jpg

First Name

Mark

Last Name

Travin

NPI

1275637597

Faculty ID

3407

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Travin's&nbsp;<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">clinical focus is on cardiac stress testing, radionuclide myocardial (perfusion and metabolic) imaging, and quantitative blood flow.</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Travin's research focus is on cardiac innervation radionuclide imaging with I-123 mIBG and analogous PET tracers, and quantitative blood flow assessment with myocardial perfusion PET.</span><quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4152

Biography

<p>Mark I. Travin, MD, FACC, MASNC, is Director of Cardiovascular Nuclear Medicine at Montefiore. He is also a Professor of Radiology and Medicine at our Albert Einstein College of Medicine. His clinical focus is on cardiac stress testing, radionuclide myocardial (perfusion and metabolic) imaging, and quantitative blood flow.</p><p>Dr. Travin earned his Bachelor of Science and Master of Science degrees in 1979 at Yale College, followed by his Doctor of Medicine degree in 1983 from the University of Pennsylvania School of Medicine. After graduating, he went on to complete both an internship and a residency in medicine at Lenox Hill Hospital. In 1986, Dr. Travin began a fellowship in cardiology at the Brown University Integrated Fellowship Program. After that, he went on to complete a clinical and research fellowship in medicine and cardiology, with emphasis in nuclear cardiology at Massachusetts General Hospital and Spaulding Rehabilitation Hospital. </p><p>Dr. Travin?s research focus is on cardiac innervation radionuclide imaging with I-123 mIBG and analogous PET tracers, and quantitative blood flow assessment with myocardial perfusion PET. He has a significant body of published research on cardiac imaging, and has received numerous awards and honors, including the Cardiology Program Director?s Training Award, and the American Society of Nuclear Cardiology 2015 Zaret-Beller Distinguished Journal of Nuclear Cardiology Service Award. </p>

Is Open Scheduling

Off

Hussein Shaqra

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Hussein

Last Name

Shaqra

NPI

1922031574

Faculty ID

19462

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

4477

Is Open Scheduling

Off

Marjan Rahmanian

https://assets.montefioreeinstein.org/profiles/images/physphoto/Rahmanian_Marjan_MD_420x504.jpg

First Name

Marjan

Last Name

Rahmanian

NPI

1033374434

Faculty ID

13978

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span>Dr. Marjan Rahmanian is an Assistant Professor of Medicine and Neurology. She is an Associate Medical Director of Cardiothoracic Intensive Care Unit at Montefiore Medical Center. She is also Medical Director of Physician Assistant Critical Care Residency program. She completed her Internal Medicine residency at Hackensack Meridian Mountainside Medical Center, followed by a fellowship in Critical Care Medicine at Mount Sinai Medical Center. After completing her training, she joined the faculty of the Albert Einstein College of Medicine in New York, where she served as an Associate Director of Cardiothoracic Surgical ICU at Montefiore Medical center. As a cardiac intensivist, Dr. Rahmanian focuses on the management of post heart surgery like CABG, valve replacemant, Mechanical Circulatory Support like,ECMO, LVAD,Impella, heart and lung transplant.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>Maintaining Hemodynamic and Metabolic Homeostasis in Anheptaic Critically Ill Patients. Khan R, Go R, Kapoor S, Dharshan A, <strong>Marjan</strong> <strong>Rahmanian </strong>, Manasia A, Bassily-Marcus A, Kohli-Seth R, Oropello J, Benjamin E. CHEST. October 2012;142:390A-390A</li>
<li>The Heart Point Sign: An Ultrasonographic Confirmation Of Pneumothorax. R. Khan, M. <strong>Marjan</strong> <strong>Rahmanian</strong>, M. Kaufman, A. Bassily Marcus, J. Oropello. ajrccm-conference.2013.187.1 MeetingAbstracts.A1539</li>
<li>Cardiothoracic Surgical ICU Boot Camp can improve cardiovascular critical care knowledge among trainees. <strong>Marjan Rahmanian, </strong>MD; Lewis Eisen, MD; Adam Keene, MD; Rosemarie Conigliaro, MD; Anthony Carlese, DO ATS2018 Poster Presentation </li>
<li>Midodrine: Breaking New Ground in The Treament of Chylothorax: Dolly Patel, DO; <strong>Marjan Rahmanian, </strong>MD; Javed Iqbal, MD; Scott Scheinin, MD; Joshoua Lee, MD; Harish Seethamraju, MD Chest 2019 Poster Presentation</li>
<li>Lactate Dehydrogenase is Associated with Hemorrhagic Stroke During Extracorporeal Membrane Oxygenation for COVID-19 <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Saeed, O.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Uehara, M.</a>; <strong>Marjan</strong> <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank"><strong>Rahmanian</strong>.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Chen, J. T.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Carlese, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mohamed, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Ashley, J.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mellas, N.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Forest, S.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Goldstein, D.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Jorde, U.</a>.<em>ASAIO Journal ; 68(Supplement 3):19, 2022.</em></li>
<li><a href="https://einstein.pure.elsevier.com/en/publications/hiv-dr-heartkidney-t…; target="_blank">HIV D+/R+ heart/kidney transplantation: First case report</a> <a href="https://einstein.pure.elsevier.com/en/persons/vagish-s-hemmige&quot; target="_blank">Hemmige, V.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/omar-saeed&quot; target="_blank">Saeed, O.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yoram-a-puius&quot; target="_blank">Puius, Y. A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yorg-al-azzi&quot; target="_blank">Azzi, Y.</a>, Colovai, A., Borgi, J., <a href="https://einstein.pure.elsevier.com/en/persons/daniel-j-goldstein&quot; target="_blank">Goldstein, D. J.</a>, Marjan Rahmanian, <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese&quot; target="_blank">Carlese, A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/ulrich-p-jorde&quot; target="_blank">Jorde, U. P.</a> &amp; <a href="https://einstein.pure.elsevier.com/en/persons/snehal-r-patel&quot; target="_blank">Patel, S. R.</a>, Mar 2023, In: <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese&quot; target="_blank">Journal of Heart and Lung Transplantation.</a> 42, 3, p. 406-408 3 p. </li>
<li>Chest Tube Insertion, Needle Thoracostomy, And Pericardiocentesis During In-hospital Cardiac Arrest <a title="Luke Andrea" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Luke Andrea</a>, Marjan Rahmanian, <a title="Anthony Carlese" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Anthony Carlese</a>, <a title="Ariel Shiloh" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Ariel Shiloh</a>, <a title="Rithvik Balakrishnan" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Rithvik Balakrishnan</a>, <a title="Aron Soleiman" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Aron Soleiman</a>, <a title="Michelle Gong" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Michelle Gong</a> and <a title="Ari Moskowitz" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Ari Moskowitz</a> Circulation. 2022;146:A247</li>
</ol>

EMR ID

5749

Is Open Scheduling

Off

Moyses Niremberg

https://assets.montefioreeinstein.org/profiles/images/physphoto/Niremberg_Moyses_MD_420x504.jpg

First Name

Moyses

Last Name

Niremberg

NPI

1861599698

Faculty ID

2623

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4337

Is Open Scheduling

Off

Michel Nassar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e21f1a40-bb36-11ec-bd24-2927171ec855.jpg

First Name

Michel

Last Name

Nassar

NPI

1851646558

Faculty ID

14086

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Clinical interests include minimally invasive airway surgery and reconstruction, and the medical and surgical management of pediatric hearing loss, including endoscopic ear surgery, cochlear implants and bone anchored hearing aids (BAHA).<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

In addition to his interests in the use of simulation in medical education, Dr. Nassar also has an interest in congenital cytomegalovirus (CMV) and hearing loss, including targeted CMV screening and the use of Valganciclovir for CMV-infected hearing-impaired infants (ValEAR).<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

5768

Biography

<p>Michel Nassar, MD, MSc, is Director, AeroDigestive Program at Children&rsquo;s Hospital at Montefiore, and Co-Director, CranioFacial Clinic and Associate Professor of Otolaryngology at Montefiore-Einstein. Dr. Nassar takes a multidisciplinary approach to patients with complex aerodigestive disease. His clinical interests include minimally invasive airway surgery and reconstruction, and the medical and surgical management of pediatric hearing loss, including endoscopic ear surgery, cochlear implants and bone anchored hearing aids (BAHA). He also has expertise in the medical and surgical management of velopharyngeal disorders.</p><p>Dr. Nassar earned his medical degree at Saint Joseph University in Beirut, Lebanon in 2005. He began his postgraduate training in France, completing an otolaryngology residency at Hotel Dieu de France Hospital in 2010 and his Masters in Surgical Sciences and pediatric otolaryngology fellowship in 2012. He then came to the United States, completing a pediatric otolaryngology fellowship at Cincinnati Children&rsquo;s Hospital in 2013.</p><p>In addition to his interests in the use of simulation in medical education, Dr. Nassar also has an interest in congenital cytomegalovirus (CMV) and hearing loss, including targeted CMV screening and the use of Valganciclovir for CMV-infected hearing-impaired infants (ValEAR). His work has been shared through peer-reviewed journals and oral presentations. He is also a reviewer for <em>Laryngoscope, the International Journal of Pediatric Otorhinolaryngology and the European Annals of Otorhinolaryngology</em>.</p><p>Dr. Nassar is a member of the American Academy of Otolaryngology&ndash;Head and Neck Surgery, the American Academy of Pediatrics and the International Federation of Oto-Rhino-Laryngological Societies. He has been listed among the <em>New York Times</em>&rsquo; Super Doctors - Rising Stars.</p>

Is Open Scheduling

On

Zocdoc Link

Shrivatsa Nadiger

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2f0fff80-470c-11ec-a9e7-9bd94149ce2f.jpg

First Name

Shrivatsa

Last Name

Nadiger

NPI

1417132218

Faculty ID

15176

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

90060

Is Open Scheduling

Off